The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
about
Aminoglycoside Prescribing and Surveillance in Cystic FibrosisPharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapySurviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008Bench-to-bedside review: microdialysis in intensive care medicine.The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenem"One-size-fits-all"? Optimizing treatment duration for bacterial infectionsVentilator-associated pneumonia: diagnosis, treatment, and preventionAntimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration.Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patientsActivities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administrationActivities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infectionBactericidal activity of gentamicin against Enterococcus faecalis in vitro and in vivo.In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis.Disposition kinetics of levofloxacin in sheep after intravenous and intramuscular administrationFood and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies.PA-824 exhibits time-dependent activity in a murine model of tuberculosis.Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery.In vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem.An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics.Teicoplanin dosing strategy for treatment of Staphylococcus aureus in Korean patients with neutropenic feverPharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.Ciprofloxacin pharmacokinetics in burn patients.Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humansActivities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MICIssues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysisThe changing face of antibiotic prescribing: the mutant selection window.Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humansThe effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.
P2860
Q22306318-BE9A5D57-9507-40A1-8F05-FD26E124D37DQ24519008-0AC6A8F4-ADBF-4614-826D-124CC52E7D68Q24644984-FDB4BF51-649A-4BFD-B409-A2CD9E5802E4Q24799689-A02D7269-1837-4956-8A73-71ADD6BA55F8Q28289744-0A759423-9D57-47EC-93DB-413598C1AE66Q28478851-4942D75B-B718-4352-AA8A-1C1C432351A5Q29012676-9C1800AF-0078-413C-A47C-8C92540828C1Q30326190-D0D35743-54A4-4438-83C3-13BD46AD913CQ33559047-079E83A1-D527-4AA7-9485-A856656C544BQ33802909-016821EE-0335-4A06-8128-D2B731C652FCQ33819854-479EC27C-E61E-44D3-926F-87722AED68C6Q33977488-58BFBB09-8944-4463-931D-20DFB91FC32BQ33978925-3F15C141-28ED-4D04-9F32-1C34CFDCF6E4Q33979054-BC871C82-FE92-4EA1-BF15-8D7B8EC4B345Q33979347-17DA0A6A-0202-4536-8222-69EBDC0D85F4Q33979426-732829F8-A92E-4CC5-80A4-C75AAFB499AFQ33980188-783CDD2B-ABD5-4320-85AD-5D3FA2472751Q33981993-51B22517-414A-4057-A8C0-7BA5EFFA55C2Q33982098-DFFB7D08-2C0F-484C-A478-EE2E7CB6DE2FQ33983364-08CC3028-3703-4436-87A1-0FC3B6E8D281Q34139031-367A1FDC-A893-4291-9F50-A90FED77E386Q34271413-73274027-0669-4A1D-8AD3-9AE9920D42C5Q34373826-F8155B98-09DF-4228-B09C-C7509F13CE93Q34483632-7FD84DD4-0C92-46EA-88BA-A74537DFB704Q34527809-315EBDFB-288A-472A-B10E-35E69FD2E25AQ34824344-76E87BED-46F2-4707-A7B9-0DF006025575Q34922257-04349640-5664-44A5-B402-BEC70C5E8479Q35014842-0CFD4A66-8A1A-41CD-822E-6E4F9B01B7E0Q35102656-B256CC21-F96D-446D-A66F-45E3FAE9106FQ35124279-8970E7BD-1FEF-462B-9505-C7322444864BQ35129720-1B9AB2C1-095E-4E82-AADE-AFE812ECE1EFQ35138007-5A81393F-EE92-4A86-A6E8-5D4404AB39E9Q35139365-449778F8-12D5-4F93-8AE4-FAAE85734B49Q35201049-F1F077CF-0433-4058-BBF3-C14FEC3B9EAAQ35637864-460C70AB-3CFA-4D18-9D1D-D7DACDA8C3EEQ35754443-1574894D-8A50-41B3-B7D0-CD8CC97AD00FQ35825356-EE0FBD47-C61F-4435-A2ED-DF22132E87AEQ35875929-584B24BE-B859-4A36-8588-75BA7E8AD96BQ36047112-6B030816-F6A8-415E-AE7C-888B9571894FQ36055066-0ED4C352-B20A-44FD-B26E-BCF965D9BDC2
P2860
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
The importance of pharmacokine ...... Focus on antibacterial agents.
@en
type
label
The importance of pharmacokine ...... Focus on antibacterial agents.
@en
prefLabel
The importance of pharmacokine ...... Focus on antibacterial agents.
@en
P2093
P1476
The importance of pharmacokine ...... Focus on antibacterial agents.
@en
P2093
G S Zimmer
J J Schentag
P S McKinnon
P304
P356
10.2165/00003088-199528020-00005
P577
1995-02-01T00:00:00Z
P6179
1004886106